InvestorsHub Logo
Followers 70
Posts 11644
Boards Moderated 0
Alias Born 01/05/2018

Re: Alleyba1 post# 641

Wednesday, 07/06/2022 4:47:28 PM

Wednesday, July 06, 2022 4:47:28 PM

Post# of 917
Veru (VERU) Received its Third Buy in a Row

Source: TipRanks
After H.C. Wainwright and Oppenheimer gave Veru (NASDAQ: VERU) a Buy rating last month, the company received another Buy, this time from Brookline Capital Markets. Analyst Kumaraguru Raja reiterated a Buy rating on Veru today and set a price target of $31.00. The company's shares closed last Wednesday at $13.03. According to TipRanks.com, Raja is a 2-star analyst with an average return of -0.2% and a 33.5% success rate. Raja covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Oncternal Therapeutics, and Caladrius Biosciences. Veru has an analyst consensus of Strong Buy, with a price target consensus of $34.00.
https://www.tipranks.com/news/blurbs/veru-veru-received-its-third-buy-in-a-row?utm_source=advfn.com&utm_medium=referral
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VERU News